Equity Overview
Price & Market Data
Price: $1.08
Daily Change: +$0.01 / 0.93%
Daily Range: $1.07 - $1.17
Market Cap: $89,641,296
Daily Volume: 1,214,507
Performance Metrics
1 Week: -27.52%
1 Month: -22.30%
3 Months: 0.47%
6 Months: -25.00%
1 Year: -44.33%
YTD: -15.62%
Company Details
Employees: 22
Sector: Health technology
Industry: Biotechnology
Country:
Details
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.